Evidence Level
NAC (N-Acetyl Cysteine) is a versatile amino acid supplement with well-documented benefits across various health conditions. As a precursor to glutathione, NAC plays a critical role in antioxidant defense and cellular protection. Recent studies highlight its efficacy in psychiatric conditions, including depression and substance use cravings. A 2024 systematic review and meta-analysis of 12 studies (904 patients) demonstrated that NAC significantly reduced depression scores compared to placebo (SMD = -0.24; P = .02) (Peng et al., 2024). Additionally, a meta-analysis by Winterlind et al. (2024) found that NAC effectively reduces substance use cravings, supporting its role in addiction management.
NAC also exhibits mucolytic properties, offering benefits for respiratory health. A 2024 study by Papi et al. highlighted its effectiveness in managing Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis, with distinct meta-analyses confirming its therapeutic value in these conditions (Papi et al., 2024). Furthermore, NAC has shown promise in improving outcomes for women with Polycystic Ovary Syndrome (PCOS). A 2025 systematic review of 22 studies (n=2515) found that NAC significantly increased progesterone levels and endometrial thickness compared to placebo or other drugs (Viña et al., 2025).
Despite its broad applications, some studies have reported limited efficacy in specific contexts. For instance, a 2024 meta-analysis by Koh et al. found no significant improvement in biochemical markers or clinical outcomes after liver resection with NAC administration (Koh et al., 2024). These findings underscore the importance of targeted use based on individual health needs.
Overall, NAC remains a valuable supplement with evidence-based applications across multiple domains, supported by rigorous research.